Skip to main content
Kesimpta

Please select your country (language)

Austria (Deutsch)

Belgium (Nederlands)

Denmark (Dansk)

France (Français)

Iceland (Islenska)

Lithuania (Lietuvių kalba)

Malta (Malti)

Portugal (Português)

Spain (Español)

Bulgaria (Български)

Croatia (Hrvatski)

Estonia (Eesti keel)

Germany (Deutsch)

Ireland (English)

Luxembourg (Français)

The Netherlands (Nederlands)

Romania (Română)

Sweden (Svenska)

Belgium (Français)

Cyprus (Ελληνικά)

Finland (suomi)

Greece (Ελληνικά)

Italy (Italiano)

Luxembourg (German)

Norway (Norsk)

Slovakia (Slovenčina)

UK-Northern Ireland (English)
 

Belgium (Deutsch)

Czech Republic (Česky)

Finland (Svenska)

Hungary (Magyar)

Latvia (Latviešu valoda)

Malta (English)

Poland (Polski)

Slovenia (slovenščina)

Legal -Malta
  • Termini tal-Użu
  • Politika dwar il-Cookies
  • Settings tal-Cookies
© 2025 Novartis CM2204077892 April 2022

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please refer to the Package Leaflet for more information.